PD-MCI的预后

更新于 2026年11月19日 版权声明
六、PD-MCI的预后

目前关于PD-MCI 的进展及转归研究很少,但并非所有的PD-MCI 都会进展为PDD。有研究显示,非痴呆PD 患者在2~5年后有20%~60%进展为PDD[18]。Janvin 等[19]发现,62%的PD-MCI 患者在4年后转变为PDD,而20%的认知正常的PD 患者进展为PDD,4年后PDD 转化发生率如下:多领域为63%、非记忆性单一领域为69%、记忆性单一领域为40%、正常认知为20%。CamPaIGN研究随访3~5年后,10%的患者被诊断为痴呆,57%的患者为认知功能障碍,大部分是额叶纹状体区损害。这表明PD-MCI 患者有很高的风险进展为PDD[18]。因此,针对PD-MCI 向PDD的转化因素及延缓PDD的发生的各项研究具有重大意义。

参考文献

[1]Williams-Gray CH,Foltynie T,Brayne CE,et al.Evolution of cognitive dysfunction in an incident Parkinson's disease cohort[J].Brain,2007,130(7):1787-1798.

[2]Foltynie T,Brayne CE,Robbins TW,et al.The cognitive ability of an incident cohort of Parkinson's patients in the UK.The CamPaIGN study[J].Brain,2004,127(Pt 3):550-560.

[3]Muslimovic D,Post B,Speelman JD,et al.Cognitive profile of patients with newly diagnosed Parkinson disease[J].Neurology,2005,65(8):1239-1245.

[4]Aarsland D,Bronnick K,Williams - Gray C,et al.Mild cognitive impairment in Parkinson disease:a multicenter pooled analysis[J].Neurology,2010,75(12):1062-1069.

[5]Litvan I,Aarsland D,Adler CH,et al.MDS Task Force on mild cognitive impairment in Parkinson's disease:critical review of PD-MCI[J].Mov Disord,2011,26(10):1814-1824.

[6]Litvan I,Goldman JG,Troster AI,et al.Diagnostic criteria for mild cognitive impairment in Parkinson's disease:Movement Disorder Society Task Force guidelines[J].Mov Disord,2012,27(3):349-356.

[7]Caviness JN,Driver - Dunckley E,Connor DJ,et al.Defining mild cognitive impairment in Parkinson's disease[J].Mov Disord,2007,22(9):1272-1277.

[8]Savica R,Grossardt BR,Bower JH,et al.Incidence of dementia with Lewy bodies and Parkinson disease dementia[J].JAMA Neurol,2013,70(11):1396-1402.

[9]Lewis SJ,Slabosz A,Robbins TW,et al.Dopaminergic basis for deficits in working memory but not attentional set - shifting in Parkinson ' s disease[J].Neuropsychologia,2005,43(6):823-832.(https://www.daowen.com)

[10]Goldman JG,Litvan I.Mild cognitive impairment in Parkinson's Disease[J].Minerva Med,2011,102(6):441-459.

[11]Cools R,Lewis SJ,Clark L,et al.L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson ' s disease[J].Neuropsychopharmacology,2007,32(1):180-189.

[12]Braak H,Rub U,Jansen Steur EN,et al.Cognitive status correlates with neuropathologic stage in Parkinson disease[J].Neurology,2005,64(8):1404-1410.

[13]Braak H,Ghebremedhin E,Rub U,et al.Stages in the development of Parkinson's disease-related pathology[J].Cell Tissue Res,2004,318(1):121-134.

[14]Tiraboschi P,Hansen LA,Alford M,et al.Cholinergic dysfunction in diseases with Lewy bodies[J].Neurology,2000,54(2):407-411.

[14]Adler CH, Caviness JN, Sabbagh MN, et al.Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment[J].Acta Neuropathol,2010,120(6):827-828.

[16]Hanagasi HA,Gurvit H,Unsalan P,et al.The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia:A randomized,double-blind,placebo-controlled,multicenter study[J].Mov Disord,2011,16(10):1851-1858.

[17]Marsh L,Biglan K,Gerstenhaber M,et al.Atomoxetine for the treatment of executive dysfunction in Parkinson's disease:a pilot open-label study[J].Mov Disord,2009,24(2):277-282.

[18]Aarsland D,Bronnick K,Williams - Gray C,et al.Mild cognitive impairment in Parkinson disease:a multicenter pooled analysis[J].Neurology,2010,75(12):1062-1069.

[19]Janvin CC,Larsen JP,Aarsland D,et al.Subtypes of mild cognitiveimpairment in Parkinson's disease:progression to dementia[J].Mov Disord,2006,21(9):1343-1349.

(谢安木)

✍AI写作